Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wake up bro. If Thom stays true to his word, there should be a PR by tomorrow evening.
Good or bad it will set this board ablaze.
Only a fool would wish for anything but the best case scenario in all situations.
Though I am incredibly realistic and accurate in my posts, when it comes to a pr that could set the course towards a successful PMA I will hope, wish and pray for a positive outcome.
Normally I don’t respond to you or anyone else who finds abusive behaviour funny, but since I am no longer restricted to one post a day, I figured I’d burn one on you.
Wishing everyone the best of luck as July 20th quickly approaches.
Hopefully, after 2 years of this Thom led dog and pony show, good news is on the way. We deserve it.
I hear you Band Aid. Unfortunately, UHP’s timelines have never reflected shareholder wishes.
And UHP’s amateur submission technique is yet to live up to FDA standards.
The positive side is that if they can get the results confirmed mid month we should be away to the races.
However, until proven otherwise, Trusts words (though extremely negative and alarmist) still ring true:
“ I don't believe anything they say Dark. Learned my lesson a long time ago. If you took the amount of crap they told people that didn't come true, you would have a dinosaur pile of crap about 10 feet wide and 7 feet high. You would think the fools running this thing would be put under a deadline. Get it done by this time or you are history. That would motivate them.”
Trust“
Your confidence, though positive is also ill informed.
The presser states that the batch test results should be available mid month.
Those results (only if positive— of course pr didn’t mention this angle) will then be incorporated into the PMA. Submission date of PMA was not stated. Hence, PMA submission date shall remain unknown until we are advised. ASAP is not a date either.
They did however, commit to informing shareholders of the test results once received mid month.
“ the company now expects the full results may not be available until mid-July rather than the end of June as previously stated. UHP will issue a statement upon completion of this process. The results will be incorporated into the PMA application, which is otherwise complete, and the full application will be submitted to the FDA. The company has notified the FDA of its intention to file this revised PMA submission as soon as possible.”
Many will attempt to bend the PR to their own agenda, but my breakdown is both factual and accurate.
Rodster, making Roddy the Rodman comments. Keep ‘em coming bro.
Yes Rod almost a full year. I’m not sure if Thom knew the meaning of the word EXPEDITIOUSLY when stating this on July 15 2022.
We will work expeditiously with our manufacturing partner in the coming weeks to accomplish these remaining tasks.”
ex·pe·di·tious·ly
adverb
with speed and efficiency.
I think you had read the pr because on July 18 22 you followed with:
Thank you! We are fortunate to be on the verge of succe$$.
$5-$10+
Personally, I was hoping the correct paperwork could be submitted within 3 months.
But I also cautioned to do it right.
I never imagined they were so far off track.
“ I don't believe anything they say Dark. Learned my lesson a long time ago. If you took the amount of crap they told people that didn't come true, you would have a dinosaur pile of crap about 10 feet wide and 7 feet high. You would think the fools running this thing would be put under a deadline. Get it done by this time or you are history. That would motivate them.”
Trust
The only line that matters in the NEXT PR that will imply Hemostyp manufacturing is moving in a positive direction towards PMA:
‘…The testing of additional batch lots of Hemostyp returned favorable results indicating that Hemostyp is manufactured, packaged and shipped with specs identical to those in the human trials. These results have been incorporated into the PMA application, which is now complete, and the full application will be submitted to the FDA.
We have alerted the FDA of our intentions and expect to have confirmation within 30 days that the PMA application has been accepted and put forward for substantive review…’
If this is not the case, hopefully they are clear and to the point with what the future holds for Hemostyp and the next steps in the process.
Obviously, there is much more involved then just receiving the testing.
A clear and non-misleading PR would have stated.
…. ‘If the testing returns favorable results indicating that Hemostyp is now manufactured, packaged and shipped with specs identical to those in the human trials, “ The results will be incorporated into the PMA application, which is otherwise complete, and the full application will be submitted to the FDA.”
Good Morning Rod. Thanks for cleaning up the White Lion comments. As you know from studying the agreement the lowest WL will be issued share purchase notice is 0.2325. So you’re right, the current pps does offer the opportunity to raise funds at this time. However, the shares will be brokered, And quite likely be a large purchase of 1 million shares plus.
Hopefully, UHP has issued the PN and WL agrees to make the purchase. It would be a great injection of $$ to see this through to the finish.
If I’m correct about last week’s trading then a day like Friday saw over 100 trades go through of 4000+ shares on average.
That’s a positive sign that new investors are getting on board and/or current longs are building their positions. While some have seen it as an opportunity to jump ship and move on.
Always remember every non fiction book you’ve ever read, movie you’ve ever watched, conversation you’ve ever had is based on learnings from the past. You can’t run today if you didn’t know how to walk yesterday.
A resume is built on past experience and learning, not dreams of the future. I see you have Linkedin so just check anyones page (including Thom’s) for how they present their PAST credentials.
Since, even I can’t see the future I must continue to judge Thom on his UHP performance. To date, I and many others are not impressed.
However, if he continues to move this forward efficiently I will gladly stop saying- where was all this action two years ago- and start believing he NOW knows what needs to be done.
Of course, this can only happen if he has not IGNORED the past, but instead, LEARNED from it.
———-
As a simple poster and non insider, I don’t have real time trading data or access to PNs. So if someone wants to check my numbers or comments I’d appreciate it.
That’s so true Rod. Let’s take it a step further and Imagine if Thom and team knew how to amend a PMA within the first 6 months of his tenure.
$1.10 x 59% increase would have had us at $1.75.
Not to mention this entire process would have been completed by Summer 2022 and we’d all be counting our money.
Especially, at a very conservative $8 per share (rumored acceptable buyout)
Hopefully the NEXT PR brings more encouraging news and we push this into the 0.40s +.
(Or what would have been $2s if Team Thom was more proactive out of the gates.)
But hey, live and learn Bro, live and learn.
I agree Trust. Here’s another example of a simple PR acting as a distraction to the FACT that FDA and the European Union both recognized Hemostyp as a safe and stable device for 8 years.
This same recognized product was used in Human trials and the results are a resounding success.
Yet in Thom’s 30 months he has been unable to convince European’s or the FDA that NEWLY manufactured and packaged USA products are not only safe, but are also identical to those used in human trials.
Like you, I refuse to pat him on his back for something that should have been completed minimum 18 months ago.
For once I’m going to keep quiet and let Merriam-Webster provide my summary of this PR:
United Health Products Reiterates Guidance on FDA PMA Application Process
REITERATES
verb
: to state or do over again or repeatedly sometimes with wearying effect.
WEARYING
Adjective
exhausted in strength, endurance, vigor, or freshness
: having one's patience, tolerance, or pleasure exhausted
“Testing of these additional batches has produced satisfactory results”
SATISFACTORY
adjective
fulfilling expectations or needs; acceptable, though NOT outstanding or perfect.
PERFECT
satisfying all requirements
corresponding to an ideal standard or abstract concept
a perfect gentleman
faithfully reproducing the original
specifically
legally valid
WAVY
adjective
having a form or edge that smoothly curves in and out.
This is true, and they are the masters of giving just enough information, stated in a way to cover their backs and leave another little ray of hope to keep investors, and potential investors, eagerly anticipating the NEXT big PR.
For years the NEXT PR will be the big one.
Well, the formula is wearing thin and it has been reflected in the steady decline in pps since Thom’s arrival.
Will the NEXT PR be the big one? Or will we get just enough information to wait for the The one to follow.
June 2020 most thought COVID was the sole reason that Hemostyp wasn’t already approved. Eagerly awaiting next PR.
June 2021 most (that misread PRs) eagerly awaiting imminent approval in NEXT PR.
June 2022 all eagerly waiting for the July 2022 FDA meeting and the PR to follow.
June 2023 all eagerly await the latest product test results and the PR to follow.
So in 4 Junes(and much further back, but I made my point) Hemostyp has gone from Imminent approval, to FDA reset, and incredibly, to testing product for specs validity.
Like the $PPS this PMA is going in the wrong direction.
It reminds me of that movie:
The Curious Case of Benjamin Button.
However, if the goal was 30 months of buying opportunities then well done!
Not a “moot point” at all. In fact it’s just the opposite.
UHPs recent actions under the guidance of PMA consultants prove that.
14 months ago I correctly stated:
“There is nothing the FDA can do until UHP can prove capable of producing hemostyp gauze in the new facility exactly as they used in the human trials.
As a result, until they get a line running at Strouse (or wherever they intend to make it now) the FDA can not complete the approval.”
11 months ago UHP finally admitted (or finally just learned) this was in FACT the case.
6 months ago UHP enthusiastically stated:
“The measured physical and chemical characteristics of the new product were shown to be effectively identical to those of the HemoStyp gauze product utilized in the company’s human trial, a key step toward demonstrating a supply of equivalent product for planned commercial production. The company will now incorporate these laboratory results and other data into its PMA application for submission as soon as possible”
But 4 months ago under consultation realized to go forward with the PMA —multiple batches must be run and packaged to prove the whole process could result in Identical product to the Human Trials. And the process must be repeatable.
2Months ago the results were announced as unsatisfactory and new tests batches and packaging were ordered.
Good for UHP to NOT move forward with a PMA submission until all aspects of the product are IDENTICAL, As it would have been rejected.
The Consultant and UHP clearly agree with ME and are NOT willing to submit the results in a “give it a shot” manner going forward.
Hopefully, the current tests are a massive SUCCESS. If not, press pause and return to the drawing board until they get it right.
This is the process. FACT.
This is all very positive. Correct, the safety and superiority was proven in the human trials.
Unfortunately, the human trials were done with Chinese produced Hemostyp, meanwhile the Hemostyp UHP is proposing to the FDA is USA product that in not meeting the very strict criteria of the FDA who want the new product (once packaged and delivered to hospitals and then unpackaged in the operating room) to be identical to the Human Trials product.
Not “Effectively identical” …but . IDENTICAL. No need for adverbs. Identical is identical.
.” Last December, a batch lot of HemoStyp gauze produced under its new manufacturing arrangements was shown to have physical and chemical characteristics that were effectively identical to those of the HemoStyp product utilized in the company’s human trial. Subsequently, the company, in consultation with its regulatory consultant and reflecting feedback from the FDA, has produced additional batch lots of HemoStyp product to demonstrate consistent production, which the company believes is an important criterion for Premarket Approval.“
“ it’s just another fear tactic to spread doubt.” That’s funny. Let’s review my comment on manufacturing…:
“using two facilities seems like a logistical nightmare for a company like UHP and it is my assumption that this is a huge part of why the testing has returned unsatisfactory results which they essentially admitted.
These changes wreak havoc on the original PMA and were the reasons I stated repeatedly that major amendments were needed. “
Now IN UHPs OWN WORDS on how this affected the testing:
“ The testing results showed several anomalies in product pH level and moisture content that the company, in consultation with the laboratory leadership, believes resulted from unintended partial oxidation during the sample cutting and packaging process that was conducted by an external component supplier.”
So that topic is finished.
Next FACT, this is NOT the production technique that will be used post PMA.
And “These changes wreak havoc on the original PMA and were the reasons I stated repeatedly that major amendments were needed.”
My only OPINION (stated as feeling) was “ we will soon learn that UHP has abandoned their quest to produce Hemostyp in the USA. Hence, the emphasis that now the Cutting and packaging is happening in a USA plant, not the manufacturing. ”
Manufacturing topic was Fact based with my OPINION that UHP MAY resort to production outside of USA.
Further, the “hot takes” by definition are to create discussion. Instead posters go in defense mode.
“ Defensive aggression may be growling, snapping or biting when a dog is confronted with what he views as a threat and he is unable to avoid or escape the perceived danger. It is based in a fear which may or may not be reasonable.”
Enjoy the holiday everyone.
Wavy.
First, let me apologize, as I sometimes forget that my impeccable track record of being correct can cause great concern when I post things others don’t want to hear.
I now also realize, that even when I say “a feeling,” “could be wrong,” or “assumption” that most believe the statement which follows will come true, because it always does.
So let me reply point by point, then I have things to get back to:
“Trying to lower the value of the stock”
…. If this were true I would be saying -sell now before it hits 0.06. No, I am suggesting $2-3.50. That’s a massive 1275% return on investment at today’s market value. So I am actually being very positive.
“What test result were those Wave?”
…now, though many think my uncanny knowledge of UHP, Hemostyp and PMA guidelines means I must be connected somehow, it’s simply not the case.
Therefore, clearly I am speaking of past results. The current tests are still under way according to UHP documentation. So if you believe company officials then clearly I can’t know these results. I emphasized this by stating that ….UHP “testing has returned unsatisfactory results which they essentially admitted.” I thought these results were made clear to all in previous PRs. Which they were.
UHP stated “ with the laboratory leadership, believes resulted from unintended partial oxidation during the sample cutting and packaging process that was conducted by an external component supplier. ” for further info please see Appendix A.
Hopefully everyone can keep up, I know this is long. But I was called out, so it’s necessary.
Next : “ The other thing that made ZERO sense”
When one introduces a statement with “Just for weekendBBQ UEEC talking points. Hot take predictions: ” it should be assumed that these are Just for weekendBBQ UEEC talking points. Hot take predictions: hears what hot take means-“ a piece of commentary, typically produced quickly in response to a recent event, whose primary purpose is to attract attention.” So that was made clear in my intro. to the predictions.
In conclusion $2-3.50 is a glorious return and even if it is not what you want, in no way is a prediction of this size going to lower the price.
Yours truly,
Wavy.
PS. Please excuse any grammar or spelling errors (doubt it) as I don’t have time to review.
Also, someone with my track record of success and accuracy should never have to explain to this degree.
Appendix A:
Manufacturing and Packaging of our Products
The Company’s NORC products will be manufactured to our specifications and using our equipment through a contract manufacturing arrangement with an FDA certified supplier that maintains stringent quality control protocols to assure the uniformity and quality of all of our gauze products. Information on the manufacturing process and our manufacturer’s facility has been submitted as part of our PMA submission. Our gauze products are cut to size, packaged and sterilized by service providers in the United States.
I have a feeling we will soon learn that UHP has abandoned their quest to produce Hemostyp in the USA. Hence, the emphasis that now the Cutting and packaging is happening in a USA plant, not the manufacturing.
Could be wrong (doubtful) but Either way, using two facilities seems like a logistical nightmare for a company like UHP and it is my assumption that this is a huge part of why the testing has returned unsatisfactory results which they essentially admitted.
These changes wreak havoc on the original PMA and were the reasons I stated repeatedly that major amendments were needed.
Just for weekendBBQ UEEC talking points. Hot take predictions:
$2-3.50 With PMA
12+ months to PMA decision
24 months to acquisition.
In the mean time UHP May be presented a low ball offer of approximately $0.48.
This excludes potential pump and dumps.
Have a tremendous weekend. And RELAX a little.
Then you would agree, no one on here has any clue what Beplate’s “liquid cash flow” is.
Therefore, you also have no clue what offer he’d be willing to accept.
You have said that Beplate has “never sold a single share.” This is false. He has sold shares as low as $0.07 in the past.
Plus, He has been accused and found guilty of deliberately misleading shareholders.
That’s us….be lied and deceived us, so I wouldn’t put him on a pedestal without knowing his history.
There is a common theme amongst “longs” that Beplate would never sell below some random $pps that has been created by aggressive posters.
I’m ecstatic with any offer $3 or more and fully understand this may be out of reach. If Shareholders sign off on a $2 offer I fully accept that and will take my profits and run.
$2 is 10 times todays value, so please don’t accuse me of trying to drive the price down.
Have at it friends, looking forward to replying to your respectful posts tomorrow.
Curious that Thom would try to sell 300,000 shares at this point.
Assuming that he has actually been contacted by interested partners (as his Filings and PRs state) and that he is truly an Acquisition expert, why would he do this.
Especially, if he has any inkling that his shares could be worth over $2 - $10 per share after the “bidding war.”
Even if he’s completely out of money (which he shouldn’t be considering his past success and that he has two other jobs at this time)
I have been told I’d be smoking something if I sell at $3.10 yet our CEO acquisition expert is willing to sell at $0.25.
I’m not a market expert so would love if someone with expertise could politely offer a REALISTIC explanation for this.
I’m not questioning the product. Potential.
Again, why sell 300,000 now if they could be worth over $1M within 3 years?
What does this say about his insight into future share value?
Clearly I was using “even $1” as an example that while Thom has much to gain as long as he finds a acquiring partner, many here can still lose.
Also, if I asked you in 2018 if we would still be sitting here without a PMA and the stock at $0.20 FIVE years later you’d have called me every name in the book.
Yet, here we are. None of us would have predicted this debacle. Therefore, we certainly don’t know what shareholders would agree to in 1,2,3,4, 5 more years. That’s just crazy talk right.
Personally (meaning, my stance) I’d take my $3.10 today. However, I’m not sure how many years it will take to get there, but I’ll wait.
My Original quote: May 9th 2019.
“Meaning an aquiring Company could purchase at about $3.10. “
What is all this talk about -what he is allowed to share within the rules and regulations? Another, common line on this board.
He has nothing to share as there is nothing new to share. He refers all questions to upcoming PRs.
Also, you have no idea if the UHP executives have more to lose than most everyone here.
For all you know someone may be foreclosing on a house or not able to send a kid to college as the money tied up here is worth 1/6 if it’s value when Thom took over.
Losses are relative. A poster here has claimed to hold over 800,000 shares.
He is now sitting on a market value loss of $800,000 compared to when Thom took over.
When Thom finds a buyer for this company for even $1 per share he makes $11,000,000. Guaranteed.
While others here may lose thousands.
Do your homework.
The CEO and his team have NOT done everything possible to make this happen and maximize shareholder value, as I have outlined many times.
Being intelligent isn’t angry. It’s simply exposes what needs to be said.
Shoving your head in the sand and ignoring reality isn’t happy, its delusional.
Im out!! Long and capable of intelligent debate….and happy.
.
If it’s been a concern for 5+ years, that doesn’t make the info less valuable, but More valuable.
Perhaps 5 years ago when Human Trials were underway, or 3 years ago when PMA was starting the submission process and most here thought Approval was “imminent “, the fact that this company was running on fumes seemed manageable.
But, after 5 plus years and literally no end in sight to the PMA process, the desperation grows.
We’re past the point of cliché “PAYtience always pays” and “buying opportunities “
If this can’t get sorted out they WILL end up in a buyout situation that is Not acceptable to anyone here based on where this stock was (BTW, 5 years ago. $0.90…)
But I suppose that doesn’t matter. It’s all just “garbage”
Another statement in every 10k, 8k, most PRs for 5 plus years is that they’ve been contacted by potential partners and negotiations are underway…..
First test was rush and deemed not extensive enough.
Second test rushed and deemed unsuccessful.
Third test underway and not being rushed.
This is why these test should have been done 2 yrs ago when they claimed to have contracted a USA manufacturing co.
In fact, these tests should have been run before claiming to have left China.
This needs to get done properly once and for all. TIME IS TRULY RUNNING OUT!
Of note from 10k.
“Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern. This could make it more difficult for us to raise funds and adversely affect our relationships with creditors, investors and suppliers.
Our auditors believe that substantial doubt exists regarding our ability to remain in business. We cannot provide any assurance that we will in fact operate our business profitably or obtain sufficient financing to sustain our business in the event we are not successful in our efforts to generate sufficient revenue and operating cash flow. The expression of such doubt by our independent registered public accounting firm or our inability to overcome the factors leading to such doubt could have a material adverse effect on our relationships with prospective customers, creditors, investors and suppliers, and therefore could have a material adverse effect on our business.“
“ Let him move in silence but effectiveness..”
This isn’t a spy movie. The Equalizer isn’t coming to save the day. This is a public company.
Plus, this company pumps every bit of good news they get. So Thom’s not silent when there’s positive info (which is infrequent and often misleading)
He is certainly not Moving in “effectiveness “.
Unless, taking a Mustang that just needed a little tune up and turning it into a broken down lemon that needs a complete rebuild is effectiveness.
Well, at least that would get us to the 0.60s. I’d prefer the $1.20s where it was before Thom and his “solid team”came aboard and sunk it.
Congratulations to Thom.
He just received another 309,000 shares.
“Common Shares were issued by the Issuer to the Reporting Person pursuant to Rule 16b-3(d)(1) in payment of salary in lieu of cash payment.”
Even at these brutal prices that’s $68,000.
Remember, when Thom took over those same shares would have been worth $370,000.
So if he can just get UEEC back to where it was before he came in and destroyed it, he wins again.
You can’t teach this stuff.
So because the pps stayed within range of the past few months (which clearly it isn’t anymore) everything is cool?
Even though the range of the last few months was the lowest in 5 YEARS!
Not setting the bar to high there are you.
That’s like telling your Child who was a A+ student as a Freshman but fell to a D- as a Senior due to lazy mistakes…” that’s OK son, because you were a D student last semester as well. Who cares if you now have limited opportunities “
As Hemostyp creeps towards the finish line you want the pps to be going up not down (or equal to its worst Q in 5 years)
Whether this is a binary event or not, the higher the pps the better for maximizing value.
No matter how “positive “ you want to sound, every delay, mistake and missed opportunity causes further dilution, loans, payments via shares. That is not good for shareholder value.
Sorry for slow reply. I’m only allowed one post a day so won’t be checking in too often.
They’ve had a consultant for a long time.
Somehow he didn’t know that all of this testing had to be done in order for the PMA to progress.
If I knew- please tell me they knew.
If they truly have full access to the consultant and he didn’t advise UHP immediately upon being contracted -and learning that UHP moved factories after human trials.- that they MUST produce USA product, then yes the consultant is “that stupid to make mistakes like this.”
Second inconsistent messaging:
Originally RCA advised that if first test is successful , then within a FEW days the PMA would move forward.
Apparently Test was a success! But then new Test is ordered- why?
They never mentioned this before.
Shouldn’t experts have known this would be needed and if they did why did they say “a few days” originally???
Reason - they screwed up the test process.
Then when they do a complete test the true results come in.
You will know the true level of incompetence when we are still wondering what stage of the process we’re in as we enter 2024!
I ASSURE you.
I can and I did.
My track record of unbiased posts gives me that ability.
I can assure you the additional batches were not produced as insurance etc.
Rather, the first batch wasn’t produced and packaged for transport.
Meaning, the first batch was not a proper test to compare head to head with the product used in trials. Yet another corner cutting error by the consultant and Thom.
I feel you had it right before when you stated: “ I don't believe anything they say Dark. Learned my lesson a long time ago. If you took the amount of crap they told people that didn't come true, you would have a dinosaur pile of crap about 10 feet wide and 7 feet high.”
The human trials are void unless they can get this USA Hemostyp identical to the China Hemostyp used in trials.
The 180 day clock is the least of our worries at this point.
370 days ago and counting:
March 24 2022 -( if I knew, they knew)
“ As I mentioned before, all delays are manufacturing related.
There is nothing the FDA can do until UHP can prove capable of producing hemostyp gauze in the new facility exactly as they used in the human trials.
As a result, until they get a line running at Strouse (or wherever they intend to make it now) the FDA can not complete the approval.”
Payday for Thom on Friday—- another $15,000. Bringing his total to approximately $375,000.
Don’t forget decades:
This is when I started following ueec. It was exciting times.
United Health Products Receives Notice of Allowance for Patent
From Aug 2013 to Sep 2013
United Health Products, Inc. (OTCQB: UEEC) announced that it has received formal notification of allowance of its patent application from the U.S. Patent Office for its hemostatic gauze product, HemoStyp™, and that the patent will issue shortly. The Company is also pursuing additional applications and filings for its HemoStyp product line.
HemoStyp is an all-natural product comprised of regenerated oxidized cellulose gauze which is specifically formulated to aid in the process of hemostasis (clotting) when positioned on a cut or wound. Unlike the other products in the wound care market, HemoStyp contains no potentially harmful chemicals or animal byproducts and is hypoallergenic. Once it has completed its task, it is easily removed by dissolving it in water or saline solution. This method of removal neither disturbs the clotted surface nor encourages re-bleeding.
Dr. Phillip Forman, CEO of United Health Products, stated that, "Now that the Company has obtained full patent rights for HemoStyp, we look forward to entering the next phase of sales and marketing with our patented product."
The Company expects its first orders from the dental and medical markets as it is now pursuing multiple markets for HemoStyp including the medical, sports, dental, military, and veterinary sectors, each of which represents a multimillion dollar market.
About United Health Products, Inc.
United Health Products, Inc. (UEEC) develops, manufactures, and markets a patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp™, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com.
Safe Harbor Statement
The CTQ program and Hemostyp’s participation ended in Dec 2018.
It is not an ongoing program.
Many used to refer to this as a “fast track” program.
It was not.
What’s a PMA CTQ?
As a follow up to my deep concern for DP’s finances….:
“Sarcasm is lost on many people, in some cases more than others, because they may be missing part of a complex set of cognitive skills based in specific parts of the brain.”
He committed fraud and knew his days were numbered:
SEC June 2022
“5. As a result of Beplate's and Schiliro's fraud, UHP reported materially overstated total revenues and accounts receivable balances in its Forms 10-Q and 10-K for 2017 and 2018, each of which Beplate signed and falsely certified.”
Plus, he held one of the all time worst conference calls. :/
Yes, the mismanagement has been rampant for many many years.
Just think about how Beplate must feel.
He’s down $30 Million since he appointed this “solid team” of part time employees.